This issue of Hematology/Oncology Clinics of North America, guest edited by Drs. Bipin Savani and Mohamad Mohty, is devoted to Bone Marrow Transplantation. Articles in this issue include: Acute Myeloid Leukemia (AML); Acute Lymphoid Leukemia (ALL); Myelodysplastic Syndrome (AML); Myeloproliferative disorders (MPD); Chronic Lymphoid Leukemia; Chronic Myeloid Leukemia (CML); Multiple Myeloma and Amyloidosis; Non-Hodgkin Lymphoma (NHL); Hodgkin Lymphoma (HL); Severe Aplastic Anemia (SAA) and Paroxysmal Nocturnal Hemoglobinuria (PNH); Sickle Cell Anemia; Thalassemia; Benign immunodeficiency diseases; and Referral to transplant centers.

This issue of Hematology/Oncology Clinics, edited by Dr. Colin A. Sieff, will focus on Bone Marrow Failure. Topics include, but are not limited to, Acquired and Inherited Bone Marrow Failure; Kickapoo Joy Juice and Somatic Mutations in the Pathogenesis of AA; Somatic Mutations in Aplastic Anemia; Recent Advances and Long-term Results of Medical Treatment of AA; Upfront Matched Unrelated Donor Transplantation in AA; Significance of Clonal Mutations in the Diagnosis and Management of Myelodysplastic Syndrome; Alternate (Haploidental) Donor Transplantation in AA; Management of Diamond Blackfan Anemia and Prospects for Novel Treatment; MDS, AML and Cancer Surveillance in Fanconi Anemia; Diagnosis, Treatment and Molecular Pathology of Shwachman Diamond Syndrome; Clinical Implications of Clonal Hematopoiesis in Dyskeratosis congenita; and Germline GATA2 Mutations and Bone Marrow Failure.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Edward J. Benz, Jr. and Vijay G. Sankaran bring their considerable expertise to the topic of Thalassemia. Top experts in the field provide an overview of the history, epidemiology, pathogenic mechanisms, and clinical management of the thalassemia syndromes. - Contains 16 practice-oriented topics including molecular basis and genetic modifiers of thalassemia; fetal hemoglobin in thalassemia; clinical complications and their management; iron chelation in thalassemia; fertility and pregnancy in women with transfusion-dependent thalassemia; gene therapy and genome editing in thalassemia; emerging medical therapies for thalassemia; and more. - Provides in-depth clinical reviews on thalassemia, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, edited by Dr. Ali Taher, focuses on Thalassemia. Topics include, but are not limited to, Molecular basis and genetic modifiers; Evolving spectrum of epidemiology; Clinical classification; Ineffective erythropoiesis, anemia and iron overload; Hypercoagulability and vascular disease; Clinical complications and their management; Transfusion and iron chelation therapy; Hematopoietic Stem Cell Transplantation in Thalassemia; Gene therapy and genome editing; Emerging therapies; Quality of life; Advances in understanding pathophysiology and treatment of fertility, pregnancy, and prenatal diagnosis in Thalassemia; and MRI for iron overload.

This issue of Hematology/Oncology Clinics, Guest Edited by Drs. Rachael Grace and Russell E. Ware, will focus on Pediatric Hematology. This issue is one of six selected for the year by the series Consulting Editors, George P. Canellos and H. Franklin Bunn. Topics include, but are not limited to, Rare Congenital Hemolytic Anemias, Sickle Cell, Thalassemia, Neutropenia and rare leukocyte disorders in children, Primary and Secondary Immune cytopenias, Disorders of Iron overload, Disorders of Iron metabolism, Approach to Hemophilia in a Changing Treatment Landscape, Von Willebrand disease, Inherited platelet disorders, Thrombosis, Diagnostic evaluation and medical approach to complications and treatment of vascular anomalies, New approaches and trials in Transfusion Medicine, and Updates in Neonatal Hematology.

In this issue of Hematology/Oncology Clinics, guest editors Drs. Sophie Lanzkron and Jane Little bring their considerable expertise to the topic of Sickle Cell Syndromes. Top experts in the field cover key topics such as structural racism and impact on sickle cell disease (SCD); pathophysiology and biomarkers of SCD; genetic modifiers of SCD; allogeneic transplant and gene therapy: reproductive health; chronic pain; and more. - Contains 16 relevant, practice-oriented topics including innovative therapies, addressing challenging complications, novel science on mechanisms of disease; preventing cognitive decline in people with SCD; quality of life in SCD; and more. - Provides in-depth clinical reviews on sickle cell syndromes, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Jennifer R. Brown︎, will focus on Chronic Lymphocytic Leukemia. This issue is one of six selected each year by our series consulting editors, Dr. George P. Canellos and Dr. Edward J. Benz. Topics discussed in this issue will include: Chronic Lymphocytic Leukemia: Do We Know the Cell of Origin Yet?; Significance of BCR Stereotypy; Prognostic and Predictive Implications of Cytogenetics and Genomics; Role of Epigenetics in Chronic Lymphocytic Leukemia; Genomics of Resistance to Targeted Therapies; First Line Therapy for Chronic Lymphocytic Leukemia; The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia Therapy; BTK Inhibitors; Minimal Residual Disease; Should Undetectable MRD Be the Goal of Chronic Lymphocytic Leukemia Therapy?; Management of Chronic Lymphocytic Leukemia after Progression on BTK Inhibitors; Role of PI3K Inhibitors in Chronic Lymphocytic Leukemia; Can We Restore the Immunodeficiency of Chronic Lymphocytic Leukemia?; and Immune Therapy for Chronic Lymphocytic Leukemia

This issue of Hematology/Oncology Clinics, edited by Dr. Janet Abrahm, focuses on Pain Control. Topics include, but are not limited to, Complex pain assessment; Evidence-based non-pharmacologic therapies; Non-opioid pharmacologic therapies; Opioid caveats, newer agents, and prevention/management of side effects and of aberrant use; Cancer pain syndromes; Agents for neuropathic pain RX; Mechanism of and Adjuvants for bone pain; Interventional anesthetic methods; Radiation therapy methods; Rehabilitation methods; Psychological treatment; Spiritual considerations; Pain in patients with SS diseases; and Pain in HSCT patients.

This issue of Hematology/Oncology Clinics, guest edited by David P. Steensma, will cover key topics in Myelodysplastic Syndromes. This issue is one of six selected each year by our series consulting editors, George P. Canellos and Edward J. Benz. Topics discussed in this issue will include: Novel prognostic models for MDS, Evaluating MDS patients with genetic mutations that might be germline, Implications of splicing mutations in MDS for pathophysiology and therapy, Assessing quality of life in MDS/MPN overlap patients, Creation of a clinic for patients with clonal hematopoiesis, Luspatercept in MDS, Prospects for venetoclax in MDS, Treatment of acquired sideroblastic anemias, Treatment of patients with AML arising from MDS, Targeting TP53 mutations in MDS, among others.

This issue of Hematology/Oncology Clinics, Guest Edited by Dr. John P. Leonard, is devoted to Mantle Cell Lymphoma. This issue is one of six selected each year by our series Consulting Editors, George P. Canellos and Edward J. Benz. Topics discussed in this important issue include: Molecular pathogenesis of Mantle Cell Lymphoma; MCL and cell cycle dysregulation; Heterogeneity in MCL biology and outcomes; Watch and wait in mantle cell lymphoma; Limited stage mantle cell lymphoma; Initial and consolidation therapy for younger patients with MCL; Approach to the initial treatment of older patients with MCL; Current and future approaches to the use of minimal residual disease monitoring in the treatment of patients with MCL; Bruton's Tyrosine Kinase inhibitors for treatment of Mantle Cell Lymphoma; BTKi resistance in MCL; Blastoid MCL; Allogeneic transplant and CAR-T cell therapy in MCL; Quality of life considerations and chronic therapy in management of patients with MCL; and Key clinical and translational research questions.